Fierce Pharma Asia—Takeda's cell, gene therapy deals; BMS-BeiGene Abraxane brawl
Takeda doubles down in cell and gene therapy with new deals with Immusoft and Poseida Therapeutics. Bristol Myers Squibb is pulling the plug on its Abraxane China licensing deal with BeiGene amid legal tension. And more.
Source: fiercepharma.com